Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Sagimet Biosciences (SGMT) reported a wider third-quarter net loss while advancing its U.S. Phase 3 AURORA trial of denifanstat for acne. Net loss was $19.149 million, versus $12.908 million a year earlier, as research and development expense increased to $16.340 million from $9.730 million.
The first AURORA patient was dosed in October. Sagimet expects topline results in the second half of 2027. Ascletis’ China open-label extension showed a 57% global assessment success rate at 52 weeks, with no adverse event-related permanent discontinuations.
An October stock and pre-funded warrant offering raised approximately $115.0 million gross. September 30 cash and investments were $275.822 million; pro forma funds were $355.8 million including additional October proceeds. Sagimet expects funding through mid-2029, including the AURORA readout and potential U.S. application for approval, and plans a TVB-3567 Phase 2 trial by year-end 2026.
Sagimet Biosciences (SGMT) granted 63,600 stock options to two newly hired employees on October 28, 2026, as employment inducements. The awards cover Series A common stock under the Nasdaq Rule 5635(c)(4) exception. Their exercise price equals the stock’s closing price on the Nasdaq Global Market that day.
The options have a ten-year term and vest over four years, subject to continued service. Management will also participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 9, 2026, at 10:30am ET.
Sagimet Biosciences (Nasdaq: SGMT) has dosed the first patient in AURORA, its U.S. Phase 3 trial of denifanstat for moderate to severe acne. The randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of 50 mg once daily. It is designed to enroll approximately 800 U.S. patients aged 12 and older, including an expected 450 adolescents aged 12 to 17.
AURORA includes a 12-week blinded treatment period followed by a 40-week extension in which eligible patients receive treatment openly. Sagimet expects topline results in the second half of 2027; the trial is intended to support a potential U.S. New Drug Application submission. Denifanstat inhibits fatty acid synthase, an enzyme involved in fat production. Ascletis holds an exclusive license in China, while Sagimet is developing denifanstat in the rest of the world.
Sagimet Biosciences (SGMT) announced 52-week acne results from license partner Ascletis’ Phase 3 denifanstat extension trial, including 57% IGA success. IGA is the Investigator’s Global Assessment of acne severity. Total lesions fell 72% and inflammatory lesions fell 77% from baseline. Denifanstat was generally well-tolerated, with continued improvement across efficacy endpoints.
The China trial was an open-label extension of a 12-week placebo-controlled study; safety was its primary endpoint and efficacy was secondary. Clinical and mechanistic data are being presented at the October 8–11, 2026 Fall Clinical Dermatology Conference in Las Vegas. Ascletis’ application for approval in China was accepted in December 2025. Sagimet’s U.S. Phase 3 AURORA trial is screening patients, with sites activated and institutional review board approvals in place.
Sagimet Biosciences (SGMT) closed its underwritten offering of Series A common stock and pre-funded warrants, raising approximately $115.0 million in gross proceeds.
The offering included 8,750,010 shares at $10.00 each and pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant. The warrants are immediately exercisable at $0.0001 per share. Gross proceeds exclude underwriting discounts, commissions and other offering expenses. Sagimet intends to use net proceeds alongside existing funds for a Phase 3 acne trial of denifanstat, its pre-launch activities, TVB-3567 through Phase 2 topline results, and its topical FASN inhibitor program through an investigational new drug application submission.
Sagimet Biosciences (SGMT) priced an underwritten offering expected to raise approximately $115.0 million in gross proceeds before underwriting deductions and expenses.
The offering includes 8,750,010 Series A common shares at $10.00 each and pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant. Closing is expected on or about October 1, 2026, subject to customary closing conditions. Commodore Capital is leading the financing. Sagimet intends to use net proceeds and existing funds for a Phase 3 denifanstat acne trial, denifanstat pre-launch activities, TVB-3567 through Phase 2 topline results, and its topical FASN inhibitor program through submission of an investigational new drug application, alongside general corporate purposes.
Sagimet Biosciences (SGMT) announced 52-week results from license partner Ascletis’ Phase 3 open-label extension trial of denifanstat in moderate to severe acne.
The China trial included 240 patients: 116 previously given denifanstat and 124 previously given placebo during a 12-week trial. Both groups received denifanstat during the 40-week extension. At trial end, treatment success was 56.7%; mean total, inflammatory and non-inflammatory lesion counts fell 71.8%, 76.9% and 66.9%, respectively, from the original trial baseline.
No adverse event-related permanent discontinuations or drug-related serious adverse events occurred. Treatment-related dry skin affected 7.1% and dry eye 5.9%. Sagimet expects screening for its U.S. AURORA Phase 3 trial to begin in October 2026, with first patient enrollment shortly thereafter; it plans to use the 50 mg dose.
Sagimet Biosciences (SGMT) will host a September 30 virtual event on denifanstat’s China trial extension and planned U.S. Phase 3 study.
In the 52-week open-label extension run by license partner Ascletis, subjects showed improvements on all efficacy endpoints, which were secondary endpoints, beyond those observed at 12 weeks in the original trial. Denifanstat was generally well tolerated in both trials. Sagimet expects to begin its U.S. AURORA Phase 3 trial in the fourth quarter of 2026.
Sagimet Biosciences (SGMT) will participate in two investor conferences in September 2026 in New York. Management joins the Cantor 2026 Global Healthcare Conference on September 9, 2026, including a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. A webcast of the fireside chat and a 90-day replay will be accessible via the Investors & Media section of the company’s website.
Sagimet Biosciences (Nasdaq: SGMT) reported operational progress for its AURORA U.S. Phase 3 trial of FASN inhibitor denifanstat in moderate to severe acne. All clinical trial sites have been identified and a CRO has been retained, with patient screening expected to begin in October 2026 and first enrollment planned for Q4 2026.
According to Sagimet, AURORA is planned to enroll about 800 U.S. patients, including roughly 450 adolescents, over around six months. The study includes a 12-week randomized, double-blind period with co-primary endpoints, followed by a 40-week open-label extension to assess long-term safety, and the company anticipates submitting an NDA after completion of the 12-week phase.